Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr;21(4):431-433.
doi: 10.1080/14760584.2022.2031986. Epub 2022 Jan 31.

Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women

Francesco Lapi  1 , Ettore Marconi  1 , Pier Mannuccio Mannucci  2 , Claudio Cricelli  3
Affiliations
Editorial

Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women

Francesco Lapi et al. Expert Rev Vaccines. 2022 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Distribution of venous thromboembolism (VTE) risk among subjects with a history of cerebral venous sinus thrombosis (CVST) and general population included according to age and risk categories. Solid line: cutoff point 1.01 (risk of VTE equal to 0.03 per 1000); dashed line: cutoff point 1.43 (risk of VTE equal to 0.1 per 1000); dash-dotted line: cutoff point 1.80 (risk of VTE equal to 0.3 per 1000). This risk categories have been obtained using Cox’s method.
Figure 2.
Figure 2.
Distribution of venous thromboembolism (VTE) risk among subjects with a history of cerebral venous sinus thrombosis (CVST) and general population included according to age and risk categories and stratified by gender. Solid line: cutoff point 1.01 (risk of VTE equal to 0.03 per 1000); dashed line: cutoff point 1.43 (risk of VTE equal to 0.1 per 1000); dash-dotted line: cutoff point 1.80 (risk of VTE equal to 0.3 per 1000). This risk categories have been obtained using Cox’s method.
See this image and copyright information in PMC

References

    1. Klok FA, Pai M, Huisman MV, et al. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 2022;9(1):e73–e80. - PMC - PubMed
    1. Marchandot B, Carmona A, Trimaille A, et al. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis. J Thromb Thrombolysis. 2021;52(3):689–691. - PMC - PubMed
    1. Greinacher A, Selleng K, Palankar R, et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021;138(22):2256–2268. - PMC - PubMed
    1. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124–2130. - PMC - PubMed
    1. Simpson CR, Shi T, Vasileiou E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021;27(7):1290–1297. - PMC - PubMed

Publication types

Substances

LinkOut - more resources